Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma

Kelun-Biotech and Harbour BioMed received China NMPA approval of the IND application for SKB575/HBM7575 for asthma, advancing the asset to clinical development. The long-acting bispecific antibody targets TSLP and a second undisclosed target, with expected human dosing intervals of >3 months based on preclinical half-life data. The news is a positive regulatory milestone but does not yet include efficacy or dosing results.

Analysis

This is a platform-validating milestone, not an earnings event. The value is in derisking the thesis that the pair can keep advancing one asset across two inflammatory indications, but the market should discount most of the economics until there is human PK/PD and a safety signal that supports the long-dosing claim. For Kelun-Biotech, the read-through is more about higher probability of future partnering leverage than near-term revenue.

The more interesting second-order effect is competitive positioning against established asthma biologics and adjacent China-developed immunology assets. A truly >3-month subcutaneous dosing interval would be differentiated on convenience, but that advantage only matters if efficacy clears the bar versus entrenched TSLP/IL-4 franchises; otherwise it becomes a niche maintenance product. The undisclosed second target also cuts both ways: it creates upside optionality, but it increases diligence risk because investors cannot underwrite mechanism quality or biomarker strategy.

In the next 1-3 months, the catalyst is purely clinical execution: first patient updates, safety, and early PK. Over 6-18 months, the real re-rating event is whether the asset can show a credible separation in exacerbation control or steroid-sparing versus incumbents; absent that, this remains a story-stock trial program. If broader China biotech risk appetite fades, this kind of early-stage approval is exactly the sort of headline that gets sold into.

Contrarian view: the market may be overestimating how much value an IND approval adds in a crowded respiratory immunology space. The current setup looks like low fundamental impact but positive sentiment optionality, which argues for patience rather than chasing strength.

Key Decisions for Investors

• No immediate directional trade in 6990.HK or 02142.HK; treat this as a watch item until first human safety/PK readout. Reassess only if early data confirms durable exposure and no tolerability issues.
• If forced to express a view, prefer a small long-bias in 6990.HK only on a post-pullback basis after the first Phase I update; target is a sentiment-driven rerate, not fundamentals, with tight risk because clinical value is unproven.
• Use AstraZeneca (AZN) / Amgen (AMGN) and Sanofi (SNY) / Regeneron (REGN) as competitive benchmarks rather than direct shorts; if this program ever looks differentiated, it would pressure the TSLP/biologics growth narrative over 12-18 months.
• Set an alert on the first asthma cohort data: if dosing interval, PK, and safety are not clearly supportive by then, fade any rally in 6990.HK/02142.HK because the IND approval will have been fully digested.